



EURORDIS-Rare Diseases Europe

The Voice of Rare Disease Patients in Europe

Anja Helm

Senior Manager of Relations with Patient Organisations

Lupus Europe meeting, 28 November 2020

EURORDIS.ORG


Rare diseases

**OVER
6000**

distinct rare
diseases

Each one affects
fewer than

**1 IN
2000
PEOPLE**



All together, an
estimated

**30
MILLION PEOPLE**
are living with a rare
disease in Europe and

**300
MILLION**
worldwide



72%
of rare
diseases
are genetic

Affects between

3.5%

-

5.9%
of the population
in the course of
their lives



**NO
CURE**

for the vast
majority of
diseases and
few treatments
available

Onset of
70%
of rare
diseases is
in childhood

By connecting patients, families and patient groups, as well as by bringing together all stakeholders and mobilising the rare disease community, EURORDIS strengthens the patient voice and shapes research, policies and patient services.



Our mission

EURORDIS works across borders and diseases to improve the lives of people living with a rare disease

944

Member patient organisations

73 countries (28 EU countries)

52 National Alliances of rare disease patient organisations

Founded in

1997

Outreach to over

2,500

patient groups

78 Federations for specific rare diseases

Over

470

volunteers

40+

Staff members with offices in Paris, Brussels and Barcelona

EURORDIS Members for Lupus & Scleroderma & Sjögren

Lupus	Scleroderma	Sjogren
Association Française du Lupus et autres Maladies Auto-Immunes	Asociación de Esclerodermia Castellon	Asociación Española Síndrome De Sjögren
Lupus France	Asociación Española de Esclerodermia	Associazione Persone con Malattie Reumatiche
Association Lupus Erythematosus	Associazione Persone con Malattie Reumatiche	Association Française du Gougerot-Sjögren
	Gruppo Italiano per la lotta alla Sclerodermia	Liga Portuguesa contra as Doenças Reumáticas
	National Association ReumaZorg Nederland	
	Sklerodermie Selbsthilfe e.V.	
Lupus Europe	FESCA	Sjögren Europe





**ADVOCATING
FOR PATIENTS**



**EMPOWERING
PATIENTS**



**ENGAGING
PATIENTS**



EURORDIS
RARE DISEASES EUROPE

PATIENTS FIRST



ADVOCATING FOR PATIENTS



Iris, Ehlers-Danlos syndrome, chronic paroxysmal hemicrania, cluster headaches

EURORDIS advocates for patients

We advocate to ensure that healthcare and social policies and services, research, and the development of medicines take into account the **real needs of people living with a rare disease** and their families



European
Patient
Advocacy
Group



914027



IRDiRC
INTERNATIONAL
RARE DISEASES RESEARCH
CONSORTIUM



EUROPEAN JOINT PROGRAMME
RARE DISEASES



RARE
DISEASES
INTERNATIONAL



NGO COMMITTEE FOR
RARE DISEASES



Rare 2030
Foresight in Rare Disease Policy

Our advocacy is fuelled by **real-life experiences of the rare disease community** through the EURORDIS Rare Barometer survey programme



Rare
Barometer

A EURORDIS INITIATIVE

Major Advocacy Achievements

- **EU Regulation on Orphan Medicinal Products in 1999**
 - Creation of the **COMP - Committee for Orphan Medicinal Products at the EMA (European Medicines Agency)**, including 3 patients' representatives for the first time
- **Over 1500 Orphan Drugs Designated** & more than 100 Products approved, benefiting approximately 3 million EU patients
- **EU Regulation on Medicinal Products for Paediatric Use in 2006**
 - Creation of the **PDCO – Paediatric Committee** at the EMA, including 3 patients' representatives and their alternates
- **EU Regulation on Advanced Therapy Medicinal Products in 2007**
 - Creation of the **CAT - Committee for Advanced Therapies** at the EMA, including 2 patients' representatives and their alternates

Major Advocacy Achievements Shaping EU Rare Disease Policy

- Communication from the European Commission to the European Parliament, : « Rare Diseases: Europe's Challenge » 11 November 2008
- First comprehensive policy text addressing issues faced by RD patients, from research on RDs, to diagnosis, access to care and adapted services and development of training, education, awareness on RDs
- Council Recommendation on an Action in the field of Rare Diseases, 8 June 2009 (**Promote the adoption of RD National Plan/Strategy in EU MS**)
- EU Directive on Patients' Rights in Cross-border Healthcare, 9 March 2011
- EU Regulation on Clinical Trials, 16 April 2014
- EU "Data Protection Package", 27 April 2016

Rare Barometer, a EURORDIS initiative



High-quality evidence based survey programme capturing the patient voice and experience

Facilitate and streamline the inclusion of patient perspectives



Provide a high-quality evidence base



Support advocacy and policy making activities at EURORDIS



Promote and improve further research on patient perspectives

Survey on the impact of Covid19 on rare disease patients – Main features



18th April – 11th May



6945 respondents in Europe (RD patients and family members)



Online quantitative survey, disseminated through social media and through EURORDIS' patient organisation network



Translated in 23 languages

Exemple : Interruption of care



HOW HAS COVID-19 IMPACTED PEOPLE WITH RARE DISEASES?

A large scale quantitative survey conducted by Rare Barometer between April and May 2020 about the impact of COVID-19 on the life and care of people living with a rare disease or their carers.

COVID-19 caused a **severe disruption to care** for people living with a rare disease

Diagnostic tests

6 in 10* did not have access to diagnostics such as blood tests and medical imaging



Medical therapies

6 in 10* were unable to receive therapies such as infusions and chemotherapies



Surgery and transplants

6 in 10* saw their intervention cancelled or postponed



83% of rare disease patients' care was disrupted

Rehabilitation therapies

8 in 10* had interventions such as physiotherapy postponed or cancelled



Medical appointments

7 in 10* had appointments cancelled or postponed



Psychiatry follow-up

6 in 10* had their sessions interrupted



*of those who experienced a disruption to care.

“Cancellation of essential consultations, closure of the hospital for non-COVID patients and due to that, the non-continuation of the analysis essential to its treatment and control.”
Rare disease patient

If you would like to participate in future rare disease surveys visit eurordis.org/voices

Participate in Rare Barometer surveys and make your voice heard

<https://www.eurordis.org/voices>

Upcoming studies

Nov - Jan 2020 - The future of your rare disease. Early 2021 - Rare disease diagnosis

Use the results of former studies

http://download2.eurordis.org/rbv/covid19survey/covid_infographics_final.pdf

For results for your disease, please contact:

rare.barometer@eurordis.org



EMPOWERING PATIENTS



Kacper from Poland is living with Kawasaki disease

EURORDIS empowers patients

By uniting the rare disease community and building the capacities of patients, we empower them to become advocates equipped with the **knowledge and skills** needed to fight for better lives



EURORDIS
Membership
Meeting



European
Network of
Rare Disease
Help Lines



EURORDIS Open Academy

Current Training Offer

Blended learning

Face-to-face
training

Online sessions &
Webinars

e-Learning



EURORDIS
WINTER SCHOOL

on Scientific Innovation &
Translational Research
30 patient advocates



EURORDIS
SUMMER SCHOOL

on Medicines Research &
Development
30 patient advocates & 10
researchers



EURORDIS
DIGITAL SCHOOL

on Social & Digital Media
Online, open to all RD patient
advocates



EURORDIS
LEADERSHIP SCHOOL

on Healthcare & Research
30 ePAG Advocates - European
Patient Advocacy Groups

All trainings are in English

e-Learning: 50+ online courses

<https://openacademy.eurordis.org>

Take part in free online training

The free online modules are available for anyone to use at a time and place that is convenient.

The conditions of use for all EURORDIS training modules have been licensed with Creative Commons. [More info on conditions of use.](#)



 <p>Unit 1: Medical Research and Development</p> <p>See more...</p>	 <p>Unit 2: Ethics in Medicines Development</p> <p>See more...</p>	 <p>Unit 3: Statistics in medicines research and development</p> <p>See more...</p>
 <p>Unit 4: Benefit-risk assessment and pharmacovigilance</p> <p>See more...</p>	 <p>Unit 5: The European Medicines Agency (EMA)</p> <p>See more...</p>	 <p>Unit 6: Medical Regulatory Framework and Procedures</p> <p>See more...</p>

Take part in free online training

Learn more about rare disease research at a time and place that suits you! Take the free online modules before the 2019 edition of the EURORDIS Winter School. The conditions of use for all EURORDIS training modules have been licensed with Creative Commons.



 <p>Winter School Unit 1: Setting the landscape</p> <p>See more...</p>	 <p>Winter School Unit 2: Genetic research to clinical diagnosis of Rare Diseases</p> <p>See more...</p>	 <p>Winter School Unit 3: Sharing patient data</p> <p>See more...</p>
 <p>Winter School Unit 4: From research to therapies</p> <p>See more...</p>	 <p>Winter School Unit 5: Education</p> <p>See more...</p>	

Free Open Access



ENGAGING PATIENTS



Philipp, osteogenesis imperfecta

EURORDIS engages patients

We make possible the engagement of patients in decision-making processes so that the **patient voice is active, amplified** and meaningful in research and medicines development, as well as in both healthcare and social policies and services.

Healthcare
European
Reference
Networks

Medicines
life cycle

Research



**European
Patient
Advocacy
Group**



PARADIGM
Patients Active in Research and Dialogues
for an Improved Generation of Medicines



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

**EURORDIS EUROCAP
Programme**



COLLABORATIVE NETWORK FOR EUROPEAN
CLINICAL TRIALS 4 CHILDREN



The EURORDIS Council of National Alliances (CNA) is made up of 30+ national rare disease alliances in Europe that come together to share information & best practices



The EURORDIS Council of European Rare Disease Federations (CEF) is a platform for exchange across 70+ federations working for a disease or group of diseases.

EURORDIS volunteers at the heart of policy making

440+ volunteers involved in EURORDIS activities

Drug Information, Transparency and Access Task Force (DITA)



focusses on the areas of product information, transparency of the regulatory process and access to medicines

30+

ePAG Advocates who are members of the EURORDIS **ePAG Steering Committee** active across 24 European Reference Networks



Rare Disease Day Working Group

Co-creating the global campaign



HTA Task Force

to facilitate the participation of patients in health technology assessment activities

340+

RareConnect moderators

animate the RareConnect communities



SPAG (Social Policy Action Group) advocating for holistic & integrated care



Therapeutic Action Group (TAG), composed of EURORDIS volunteers in the scientific committees and working party at the **European Medicines Agency (EMA)**

ePAGs

302 ePAG advocates
from 263 patient organisations
of which 189 are EURORDIS
members
In 29 countries

ePAG: ERN ReCONNET (Connective tissue and musculoskeletal)

7 ePAG patient representatives:

- Belgium, Alain Cornet, Lupus Europe
- Belgium, Charissa Frank, Vlaamse Vereniging voor erfelijke Bindweefselaandoeningen
- Germany, Juergen Grunert, Deutsche Ehlers-Danlos Initiative e.V.
- Italy, Ilaria Galetti, Federation of European Scleroderma Associations
- Portugal, Ana Vieira, Liga Portuguesa contra as Doenças Reumáticas
- Portugal, Vera Guimaraes, Liga Portuguesa contra as Doenças Reumáticas
- Spain, Silvia Aguilera, , Asociación Española Del Síndrome De Rett